ACEi: Clinical Trials

3 trials of ACEi, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Terminated 1

Follow ACEi: new trials by email Literature Review of ACEi trials Research Report on ACEi

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
tacrolimus, Simulect, Cellcept - Kidney Transplantation
Phase 3CompletedAstellas Pharma Inc2812009-08-172024-11-01
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
Mycophenolate Mofetil (MMF), MMF Placebo, ACEi - IgA Nephropathy
Phase 3TerminatedSt. Joseph's Hospital and Medical Center, Phoenix1842002-01-012016-03-07
African American Study of Kidney Disease and Hypertension
MAP goal less than or equal to 92 mm Hg, MAP goal 102-107 mm Hg, Ramipril - Hypertensive Nephrosclerosis, Chronic Renal Insufficiency
Phase 3CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)10941995-02-012020-04-27

Conditions studied

Glomerulonephritis, IGA (1)  ·  Proteinuria (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Astellas Pharma Inc (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  St. Joseph's Hospital and Medical Center, Phoenix (1)

Countries

Canada (1)  ·  United States (1)

Top investigators

Ronald J Hogg, M.D. (1)

Results publications

PMID 11386927, PMID 12435255, PMID 20818902, PMID 30582281, PMID 38299639, PMID 38864363, PMID 39082471, PMID 39739990, PMID 41198855

NIH funding

U01DK048648 (1)